書籍詳細

1. メタボリックシンドロームとは

P.16 掲載の参考文献

• 1) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486-2497, 2001

• 2) World Health Organization:Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications. Part I:Diagnosis and Classification of Diabetes Mellitus. World Health Organization, Geneva, 1999
  pubmed

• 3) メタボリックシンドローム診断基準検討委員会:メタボリックシンドロームの定義と診断基準. 日本内科学会雑誌 94:794-809, 2005

• 4) MatSuzawa Y et al:Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 24:29-33, 2004
  pubmed

• 5) Ryo M et al:Adiponectin as a biomarker of the metabolic syndrome. Circ J 68:975-981, 2004
  pubmed

• 6) The examination committee of criteria for 'Obesity disease' in Japan;Japan society for the study of obesity:New criteria for 'Obesity disease' in Japan. Circ J 66:987-992, 2002

• 7) 日本糖尿病学会編:糖尿病治療ガイド2004-2005, 2004

• 8) 日本動脈硬化学会:動脈硬化性疾患診療ガイドライン2002年版

• 9) 竹内 宏ほか:日本人男性におけるMetabolic Syndromeとインスリン抵抗性の検討- 端野・壮瞥研究. 糖尿病 46:739-744, 2003

2. 動脈硬化性疾患におけるリスクファクター研究の変遷

P.21 掲載の参考文献

• 1) Kitamura A et al:Trends in the incidence of coronary heart disease and stroke and the prevalence of cardiovascular risk factors among Japanese men from 1963 to 1994. Am J Med 112:104-109, 2002
  pubmed

• 2) 第5次循環器疾患基礎調査報告 (平成12年), 厚生労働省健康局, 2002

• 3) 生活習慣病予防研究会編:生活習慣病のしおり, 社会保険出版社, 2004

• 4) Ogawa K et al:Angiographic and coronary risk factor analyses of Japanese patients with ischemic heart disease before age 40-A multicenter cooperative study-. Jpn Circ J 60:822-830, 1996
  pubmed

• 5) Reaven GM:Role of insulin resistance in human disease. Diabetes 37:1595-1607, 1988
  pubmed

• 6) Kaplan NM:The deadly quartet:Upper-body obesity, glucose intolerance, hyper-triglyceridemia, and hypertension. Arch Intem Med 149:1514-1520, 1989

• 7) DeFronzo RA, Ferrannini E:Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14:173-194, 1991
  pubmed

• 8) Kissebah A et al:Relation of body fat distribution to metabolic complications of obesity. J Clin Endocr Metab 54:254-260, 1982

• 9) Larsson B et al:Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death:13 year follow up of participants in the study of men born in 1913. Br Med J 288:1401-1404, 1984

• 10) Lapidus L et al:Distribution of adipose tissue and risk of cardiovascular disease and death:a 12 year follow up of participants in the population study of women in Gothenburg, Sweden. Br Med J 289:1257-1261, 1984

• 11) Han TS et al:Waist circumference action levels in the identification of cardiovascular risk factors:prevalence study in random sample. BMJ 311:1401-1405, 1995
  pubmed

• 12) Fujioka S et al:Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism 36:54-59, 1987

• 13) Kanai H et al:Close correlation of intra-abdominal fat accumulation to hypertension in obese women. Hypertension 16:484-490, 1990
  pubmed

• 14) Nakamura T et al:Contribution of visceral fat accumulation to the development of coronary artery disease in non-obese men. Atherosclerosis 107:239, 1994

• 15) メタボリックシンドローム診断基準検討委員会:メタボリックシンドロームの定義と診断基準. 日本内科学会雑誌 94:794-809, 2005

3. 上流因子は何か? (インスリン抵抗性か, 肥満か)

P.28 掲載の参考文献

• 1) Reaven GM:Role of insulin resistance in human disease. Diabetes 37:1595, 1988
  pubmed

• 2) DeFronzo RA, Ferannini E:Insulin resistance-A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease-. Diabetes Care 14:173, 1991

• 3) Kaplan NM:The deadly qualtet-Upper body obesity, glucose intolerance, hyperglyceridemia, and hypertension-. Arch Intern Med l49:1514, 1989

• 4) Matsuzawa Y et al:Molecular Mechanism of Metabolic Syndrome X:Contribution of Adipocytokines・Adipocyte-derived Bioactive Substances. Ann NY Acad Sci 892:146, 1999

• 5) Ruige JB et al:Insulin and risk of cardiovascular disease:a meta-analysis. Circulation 93:1809-1817, 1996

• 6) Bonora E et al:HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects:prospective data from the Verona Diabetes Complications Study. Diabetes Care 25:1135-1141, 2002
  pubmed

• 7) Savkur RV et al:Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. Nat Genet 29:4047, 2001

• 8) Kubota T et al:Lack of insulin receptor substrate-2 causes progressive neointima formation in response to vessel injury. Circulation 107:3073-3080, 2003
  pubmed

• 9) Shimomura I et al:Enhanced expression of PAI-1 in visceral fat:possible contrbutor to vascular disease in obesity. Nat Med 2:800-803, 1996
  pubmed

• 10) Matsuzawa Y et al:Adiponectin and Metabolic Syndrome. Arterioscler ThrombVasc Biol 24:29-33, 2004
  pubmed

4. 脂肪細胞―メタボリックシンドロームの細胞基盤―

P.38 掲載の参考文献

• 1) 杉原 甫:「脂肪細胞の増殖」第124回日本医学会シンポジウム記録. 2003, pp71-81

• 2) Sugihara H et al:Primary culture of unilocular fat cells:Characteristics of growth in vitro and changes in differentiation properties. Differentiation 31:42-49, 1986
  pubmed

• 3) Sugihara H et al:Primary culture of fat cells. In:Cell & Tissue Culture:Laboratory Procedures(ed by Doyle A et al), p11B:11. 1-17, John Wiley & Sons Company, Chichester UK, 1996

• 4) Sugihara et al:Proliferation of small fat cells derived from unilocular fat cells of rats in collagen gel matrix culture. Acta Histchem Cytochem 30:63-76, 1997

• 5) 杉原 甫ほか:肥満の脂肪細胞診断の試み. 肥満研究 6(2):185-191, 2000
  Medical*Online

• 6) 杉原 甫ほか:肥満についての新しい細胞生物学的分類の提唱, 肥満研究 8(2):125-130, 2002

• 7) Weisberg SP et al:Obesity is associated With macrophage accumulation in adipose tissue. JCI 112:1796, 2003
  pubmed

• 8) Xu H et al:Chronic inflammation in fat play a crucial role in the development of obesity-related insulin resistance. JCI 112:1821-1830, 2003
  pubmed

5. 内臓脂肪と皮下脂肪

P.46 掲載の参考文献

• 1) Kissebah AH et al:Relation of fat distribution to metabolic complication to obesity. J Clin Endocrinol Metab 54:254-260, 1982

• 2) 葭川明義ほか:肥満に起因・関連する各種病態と成立機序-高血圧-. 日本臨床 61:448-452, 2003

• 3) 朝川秀樹ほか:糖尿病・代謝症候群の成因と病態-内臓脂肪型肥満-. 別冊・医学のあゆみ:4-7, 2004

• 4) Maeda K et al:Analysis of an expression profile of genes in the human adipose tissue. Gene 190:227-235, 1997
  pubmed

• 5) Matsuzawa Y et al:Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 24:29-33, 2004
  pubmed

• 6) 吉池信男ほか:Body mass indexに基づく肥満の程度と糖尿病, 高血圧, 高脂血症の危険因子との関連:他施設共同研究による疫学的検討. 肥満研究 6:4, 2000

• 7) 朝川秀樹ほか:内臓脂肪型肥満と内臓脂肪症候群. 日本臨床 61:431-435, 2003
  Medical*Online

• 8) 疋田美穂ほか:肥満と高尿酸血症. 内科 92:258-262, 2003

• 9) Matsuura F et al:Effect of Visceral fat accumulation on uric acid metabolism in male obese subjects:visceral fat obesity is linked more closely to overproduction of uric acid than subcutaneous fat obesity. Metabolism 47:929, 1998
  pubmed

• 10) Maeda N et al:Adaptation to fasting by glycerol transport through aquaporin 7 in adipose tissue. Proc Natl Acad Sci USA 101:17801-17806, 2004
  pubmed

6. アディポサイトカイン

P.58 掲載の参考文献

• 1) Maeda K et al:Analysis of an expression profile of genes in the human adipose tissue. Gene 190:227-235, 1997
  pubmed

• 2) Maeda K et al:cDNA cloning and expression of a novel adipose specific collagen- like factor, apM1(AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 221:286-289, 1996
  pubmed

• 3) Arita Y et al:Paradoxical decrease of an adipose-specific protein, adiponecbin, in obesity. Biochem Biophys Res Commun 257:79-83, 1999
  pubmed

• 4) Nishizawa H et al:Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 51:2734-2741, 2002
  pubmed

• 5) Okamoto Y et al:An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. Horrn Metab Res 32(2):47-50, 2000
  pubmed

• 6) Ouchi N et al:Novel modulator for endothelial adhesion molecules:adipocyte-derived plasma protein adiponectin. Circulation 100:2473-2476, 1999
  pubmed

• 7) Kumada M et al:Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 23:85-89, 2003
  pubmed

• 8) Pischon T et al:Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291:1730-1737, 2004
  pubmed

• 9) Matsuda M et al:Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem 277:37487-37491, 2002

• 10) Okamoto Y et al:Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 106:2767-2770, 2002
  pubmed

• 11) Fruebis J et al:Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 98:2005-2010, 2001
  pubmed

• 12) Yamauchi T et al:The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941-946, 2001
  pubmed

• 13) Maeda N et al:Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 8:731-737, 2002
  pubmed

• 14) Kondo H et al:Association of adiponectin mutation With type 2 diabetes:a candidate gene for the insulin resistance syndrome. Diabetes 51:2325-2328, 2002
  pubmed

• 15) Ouchi N et al:Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 107:671-674, 2003
  pubmed

• 16) Ouchi N et al:Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension 42:231-234, 2003
  pubmed

• 17) Kamada Y et al:Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology 125:1796-1807, 2003
  pubmed

• 18) Hotamisligil GS et al:Adipose expression of tumor necrosis factor-alpha:direct role in obesity-linked insulin resistance. Science 259:87-91, 1993
  pubmed

• 19) Shimomura et al:Enhanced expression of PAI-1 in visceral fat:possible contributor to vascular disease in obesity. Nat Med 2:800-803, 1996
  pubmed

• 20) Zhang Y et al:Positional cloning of the mouse obese gene and its human homologue. Nature 372:425-432, 1994
  pubmed

• 21) Shimomura et al:Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 401:73-76, 1999
  pubmed

• 22) Steppan CM et al:The hormone resistin links obesity to diabetes. Nature 409:307-312, 2001
  pubmed

• 23) Fukuhara A et al:Visfatin:a protein secreted by visceral fat that mimics the effects of insulin. Science 307:426-430, 2005
  pubmed

• 24) Furukawa S et al:Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 114:1752-1761, 2004
  pubmed

7. メタボリックシンドロームの検査とその意義

P.70 掲載の参考文献

• 1) Examination Committee of Criteria for 'Obesity Disease' in Japan;Japan Society for the Study of Obesity:New criteria for 'obesity disease' in Japan. Circ J 66:987-992, 2002

• 2) Ryo M et al:Anew simple method for the measurement of visceral fat accumulation by bioelectrical impedance. Diabetes Care 28:451-453, 2005

• 3) Gerstein HC et al:Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 286:421-426, 2001
  pubmed

• 4) Mann JF et al:Development of renal disease in people at high cardiovascular risk:results of the HOPE randomized study. J Am Soc Nephrol 14:641-647, 2003
  pubmed

• 5) 糖尿病性腎症に関する合同委員会報告. 糖尿病 44:623, 2001

• 6) Kumada M et al:Osaka CAD Study Group:Coronary artery disease:Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 23:85-89, 2003

• 7) Matsuzawa Y et al:Adiponectin and Metabolic Syndrome. Arterioscler Thromb Vasc Biol 24:29-33, 2004
  pubmed

• 8) Pischon T et al:Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291:1730-1737, 2004
  pubmed

• 9) Ryo M et al:Adiponectin as a biomarker of the metabolic syndrome. Circ J 68:975-981, 2004
  pubmed

• 10) Ouchi N et al:Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 107:671-674, 2003
  pubmed

• 11) Maeda N et al:Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 8:731-737, 2002
  pubmed

• 12) Shimomura I et al:Enhanced expression of PAI-1 in visceral fat:possible contributor to vascular disease in obesity. Nat Med 2:800-803, 1996
  pubmed

• 13) 藤代健太郎:III-2プラーク, 頸動脈エコー測定法とその意義, 古幡博編, 第1版, ベクトル・コア

8. メタボリックシンドロームの管理

P.87 掲載の参考文献

• 1) Nakamura T et al:Magnitude of sustained multiple risk factors for ischemic heart disease in Japanese employees-a case control study-. Jpn Circ J 65:11-17, 2001
  pubmed

• 2) Malik S et al:Impact of the metabolic syndrome on motality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 110:1245-1250, 2004

• 3) Lakka HM et al:The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288:2709-2716, 2002
  pubmed

• 4) Hunt KJ et al:San Antonio Heart Study:National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 110:1251-1257, 2004

• 5) メタボリックシンドローム診断基準検討委員会, メタボリックシンドロームの定義と診断基準. 日本内科学会雑誌 94:794-809, 2005

• 6) The IDF consensus worldwide definition of the metabolic syndrome, 2005

• 7) The examination committee of criteria for 'Obesity disease' in Japan;Japan society for the study of obesity:New criteria for 'Obesity disease' in Japan. Circ J 66:987-992, 2002

• 8) 糖尿病発症高危険群におけるインスリン抵抗性とその生活習慣基盤に関する多施設共同追跡調査-介入対象としての内臓肥満の意義の確立-総合研究報告書. 2001年

• 9) Ryo M et al:A New Simple Method for the Measurement of Visceral Fat Accumulation by Bioelectrical Impedance. Diabetes Care 28:451-453, 2005
  pubmed

• 10) Ryo M et al, 投稿準備中

• 11) 日本糖尿病学会編:科学的根拠に基づく糖尿病診療ガイドライン, 南江堂, 2004

• 12) Arima H et al:Validity of the JNC VI recommendations for management of hypertension in a general population of Japanese elderly. The Hayama Study. Arch Intern Med 163:361-366, 2003

• 13) 島本和明:高血圧管理・治療の新しい動向 (JNC VIと我が国の現状). 日内会誌 88:401-405, 1999

• 14) 日本高血圧学会高血圧治療ガイドライン作成委員会:高血圧治療ガイドライン2004, ライフサイエンス出版

• 15) 日本動脈硬化学会:動脈硬化性疾患診療ガイドライン
  Medical*Online

• 16) 富田真佐子ほか:血清尿酸値が諸痴患に及ぼす影響-固定集団の長期追跡調査による解析. 痛風と核酸代謝 20:91-97, 1996

• 17) 日本痛風・核酸代謝学会:高尿酸血症・痛風の治療ガイドライン

9. EBMから見たメタボリックシンドロームの薬物治療

P.99 掲載の参考文献

• 1) Yusuf S et al:HOPE Study Investigators. :Ramipril and the development of diabetes. JAMA 286 (15):1882-1885 2001

• 2) Lindholm LH et al:For the LIFE study group. :Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 20 (9):1879-1886, 2002

• 3) Lithell H et al:SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE):principal results of a randomized double-blind intervention trial. J Hypertens 21 (5):875-886, 2003

• 4) Dahlof B et al:LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):a randomised trial against atenolol. Lancet 359 (9311):995-1003, 2002

• 5) Pitt B et al:Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)Lancet 349 (9054):747-752, 1997
  pubmed

• 6) Viberti G et al:Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus:a blood pressure-independent effect. Circulation 106 (69):672-678, 2002

• 7) Parving HH et al:Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group:The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345 (12):870-878, 2001

• 8) Brenner BM et al:RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345(12):861-869, 2001

• 9) Fliser D et al:Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 110 (9):1103-1107, 2004
  pubmed

• 10) 片山茂裕:糖尿病に合併した高血圧の降圧薬の選択. 内分泌・糖尿病科 14:505, 2002

• 11) 日本臨床内科医会会誌 16(1):46-67, 2002

• 12) Progress in Medicine 17(9):2389-2392, 1997
  Medical*Online

• 13) 佐倉 宏:インスリン抵抗性改善薬のエビデンス. EBMジャーナル 6:286-292, 2005

• 14) 細川和弘:メトホルミンの有効・安全な治療へのエビデンス. EBMジャーナル 6:295-298, 2005

• 15) 井上郁夫ほか:PPARαと脂質代謝. Progress in Medicine 19:2451-2459, 1999
  Medical*Online

• 16) Dormandy JA et al; PROactive investigators:Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study(PROspective pioglitAzone Clinical Trial ln macroVascular Events):a randomised controlled trial. Lancet 366(9493):1279-1289, 2005

• 17) Aronoff S et al:Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes:a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

• 18) Satoh N et al:Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 26 (9):2493-2499, 2003
  pubmed

• 19) Koshiyama H et al:Rapid communication:inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 86(7):3452-3456, 2001
  pubmed

• 20) Takagi T et al:Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus:an intravascular ultrasound scanning study. Am Heart J 146 (2):E5, 2003
  pubmed

• 21) Maeda N et al:PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50(9):2094-2099, 2001
  pubmed

• 22) Promrat K et al:A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 39(1):188-196, 2004
  pubmed

• 23) Jeppesen J et al:Effect of metformin on postprandial lipemia in patients with fairly to poorly controlled NIDDM. Diabetes Care 17(10):1093-1099, 1994
  pubmed

• 24) Effect of intensive blood-glucose control with metformin on complications in over-weight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352 (9131):854-865, 1998
  pubmed

• 25) Sattar N et al:Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 108 (4):414-419, 2003
  pubmed

• 26) Pyorala K et al:Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome:sub-group analyses of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 27 (7):1735-1740, 2004

• 27) Freeman DJ et al:Pravastatin and the development of diabetes mellitus:evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 103 (3):357-362, 2001
  pubmed

• 28) Tenenbaum A et al:Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation 109 (18):2197-2202, 2004
  pubmed

• 29) Tenenbaum A et al:Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients. Eur Heart J. 2005 May 4;[Epub ahead of print]

• 30) Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease:the Bezafibrate Infarction Prevention(BIP) study. Circulation 102(1):21-27, 2000
  pubmed

• 31) Tenenbaum A et al:Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med 165(10):1154-1160, 2005
  pubmed